PARAMOUNT: DESCRIPTIVE SUBGROUP ANALYSES OF FINAL OVERALL SURVIVAL (OS) FOR THE PHASE III STUDY OF MAINTENANCE PEMETREXED (PEM) VERSUS PLACEBO (PLB) FOLLOWING INDUCTION TREATMENT WITH PEM PLUS CISPLATIN (CIS) FOR ADVANCED NONSQUAMOUS (NS) NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Reck, M. [1 ]
Paz-Ares, L. [2 ]
De Marinis, F. [3 ]
Molinier, O. [4 ]
Sahoo, T. Prasad [5 ]
Laack, E. [6 ]
John, W. [7 ]
Zimmermann, A. [7 ]
Visseren-Grul, C. M. [8 ]
Gridelli, C. [9 ]
机构：
[1] Hosp Grosshansdorf, Grosshansdorf, Germany
[2] Univ Hosp Virgen del Rocio, Inst Biomed Sevilla 2, Seville, Spain
[3] Azienda Osped S Camillo Forlanini, Pulomonary Oncol Unit 1, Rome, Italy
[4] Le Mans Reg Hosp, Le Mans, France
[5] Jawaharlal Nehru Canc Hosp & Res Ctr, Bhopal, India
[6] Ambulantes Krebszentrum Hamburg, Hamburg, Germany
[7] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[8] Eli Lilly, Oncol Europe, Ra Houten, Netherlands
[9] UO Oncol Med SG Moscati Hosp, Avellino, Italy
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：404 / 404
页数：1
相关论文
共 50 条
  • [31] PEMETREXED (PEM) COMBINATION THERAPY WITH CARBOPLATIN (CB) FOLLOWED BY PEM MAINTENANCE IN JAPANESE PATIENTS (PTS) WITH NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): SUBGROUP ANALYSIS OF ELDERLY PTS
    Nogami, N.
    Sekiguchi, R.
    Enatsu, S.
    Nakagawa, K.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 393 - 394
  • [32] Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials
    Scagliotti, G. V.
    Gridelli, C.
    de Marinis, F.
    Thomas, M.
    Dediu, M.
    Pujol, J. -L.
    Manegold, C.
    San Antonio, B.
    Peterson, P. M.
    John, W.
    Chouaki, N.
    Visseren-Grul, C.
    Paz-Ares, L. G.
    LUNG CANCER, 2014, 85 (03) : 408 - 414
  • [33] PEMETREXED (PEM) AND CISPLATIN (CIS) WITH CONCURRENT THORACIC RADIATION AFTER PEM plus CIS INDUCTION IN PATIENTS (PTS) WITH UNRESECTABLE LOCALLY ADVANCED (LA) NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NS-NSCLC): RESULTS IN DIFFERENT AGE GROUPS (≤70 YRS, >70 YRS)
    Garrido Lopez, P.
    Novello, S.
    Engel-Riedel, W.
    Serke, M.
    Giraud, P.
    Visseren-Grul, C. M.
    Ameryckx, S.
    Soldatenkova, V.
    Chouaki, N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [34] A phase I study of enzastaurin (Enz) combined with pemetrexed (Pem) in advanced non-small cell lung cancer (NSCLC)
    Takahashi, T.
    Yamamoto, N.
    Murakami, H.
    Ohe, Y.
    Kunitoh, H.
    Nokihara, H.
    Koshiji, M.
    Tamura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer
    Paz-Ares, Luis G.
    Altug, Sedat
    Vaury, Alexandra Thareau
    Corral Jaime, Jesus
    Russo, Francesca
    Visseren-Grul, Carla
    BMC CANCER, 2010, 10
  • [36] Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer
    Luis G Paz-Ares
    Sedat Altug
    Alexandra Thareau Vaury
    Jesús Corral Jaime
    Francesca Russo
    Carla Visseren-Grul
    BMC Cancer, 10
  • [37] FIRST LINE CHEMOTHERAPY WITH PEMETREXED PLUS CISPLATIN IN ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A COMPARISON OF TWO PHASE III TRIALS
    Scagliotti, Giorgio
    Gridelli, Cesare
    De Marinis, Filippo
    Thomas, Michael
    Dedui, Mircea
    Pujol, Jean-Louis
    Manegold, Christian
    Melemed, Symantha
    John, William
    Zimmermann, Annamaria H.
    Chouaki, Nadia
    Melemed, Allen
    Visseren-Grul, Carla
    Paz Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1160 - S1161
  • [38] PALLIATIVE RADIATION DURING PEMETREXED PLUS CISPLATIN FIRST-LINE TREATMENT OR PEMETREXED CONTINUATION MAINTENANCE TREATMENT IN ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A REPORT OF PATIENT SAFETY IN THE PARAMOUNT TRIAL
    De Marinis, Filippo
    Gridelli, Cesare
    Dediu, Mircea
    Thomas, Michael
    Pujol, Jean-Lois
    Molinier, Olivier
    Reck, Martin
    Sahoo, Tarini P.
    San Antonio, Belen
    John, William J.
    Zimmermann, Annamaria H.
    Chouaki, Nadia
    Visseren-Grul, Carla
    Paz-Arez, Luis G.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S842 - S843
  • [39] Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Manegold, C.
    Digumarti, R.
    Zukin, M.
    de Marinis, F.
    Mellerngaard, A.
    Gandara, D.
    Simms, L.
    Kaiser, C.
    Blatter, J.
    Gatzemeier, U.
    EJC SUPPLEMENTS, 2007, 5 (06): : 9 - 9
  • [40] Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Scagliotti, Giorgio
    Purvish, Parikh
    von Pawel, Joachim
    Biesma, Bonna
    Vansteenkiste, Johan
    Manegold, Christian
    Simms, Lorinda
    Posther, Sugarman Katherine
    Obasaju, Coleman
    Blatter, Johannes
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S306 - S306
12345